Your session is about to expire
β Back to Search
GLP-1 Receptor Agonist
Cohort 2 for Type 1 Diabetes
Phase 1
Waitlist Available
Research Sponsored by Hanmi Pharmaceutical Company Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
T1DM or T2DM
Female subjects must be non-pregnant and non-lactating
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month
Awards & highlights
Study Summary
This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 1 and Type 2 diabetes mellitus
Eligible Conditions
- Type 1 Diabetes
- Type 2 Diabetes
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check βYesβ for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 month
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of participants with adverse events
Secondary outcome measures
AUC of HM12470
Cmax of HM12470
Trial Design
4Treatment groups
Experimental Treatment
Group I: Cohort 4Experimental Treatment1 Intervention
T2DM: Multiple dose subcutaneous administration
Group II: Cohort 3Experimental Treatment1 Intervention
T2DM: Multiple dose subcutaneous administration
Group III: Cohort 2Experimental Treatment1 Intervention
T1DM: Multiple dose subcutaneous administration
Group IV: Cohort 1Experimental Treatment1 Intervention
T1DM: Multiple dose subcutaneous administration
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HM12470
2015
Completed Phase 1
~160
Find a Location
Who is running the clinical trial?
Hanmi Pharmaceutical Company LimitedLead Sponsor
188 Previous Clinical Trials
60,975 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger